COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office.

Elaine R Miller, Pedro L Moro, Tom T Shimabukuro, Grace Carlock, Shaeyla N Davis, Emma M Freeborn, Amy L Roberts, Julianne Gee, Allan W Taylor, Ruth Gallego, Tiffany Suragh, John R Su

Vaccine 2023 Jun 19

filter terms:

Following the authorization and recommendations for use of the U.S. COVID-19 vaccines, the Centers for Disease Control and Prevention (CDC)'s Immunization Safety Office (ISO) responded to inquiries and questions from public health officials, healthcare providers, and the general public on COVID-19 vaccine safety. We describe COVID-19 vaccine safety inquiries, by topic, received and addressed by ISO from December 1, 2020-August 31, 2022. Of the 1978 COVID-19 vaccine-related inquiries received, 1655 specifically involved vaccine safety topics. The most frequently asked-about topics included deaths following vaccination, myocarditis, pregnancy, and reproductive health outcomes, understanding or interpreting data from the Vaccine Adverse Event Reporting System (VAERS), and thrombosis with thrombocytopenia syndrome. Inquiries about vaccine safety generally reflect issues that receive media attention. ISO will continue to monitor vaccine safety inquiries and provide accurate and timely information to healthcare providers, public health officials, and the general public. Published by Elsevier Ltd.

Citation

Elaine R Miller, Pedro L Moro, Tom T Shimabukuro, Grace Carlock, Shaeyla N Davis, Emma M Freeborn, Amy L Roberts, Julianne Gee, Allan W Taylor, Ruth Gallego, Tiffany Suragh, John R Su. COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office. Vaccine. 2023 Jun 19;41(27):3960-3963